Edition:
India

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

85.68USD
2:29am IST
Change (% chg)

$0.01 (+0.01%)
Prev Close
$85.67
Open
$85.93
Day's High
$87.18
Day's Low
$85.42
Volume
426,446
Avg. Vol
210,509
52-wk High
$99.80
52-wk Low
$44.58

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: --
Market Cap(Mil.): $2,399.97
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

15 Nov 2017

BRIEF-Sage Therapeutics announces proposed public offering of common stock

* Sage Therapeutics announces proposed public offering of common stock

14 Nov 2017

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

09 Nov 2017

UPDATE 1-Sage Therapeutics postpartum depression drug meets goal in two trials

Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies, sending shares of the company up about 17 percent in pre-market trade.

09 Nov 2017

REFILE-Sage Therapeutics postpartum depression drug meets main goal

Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

09 Nov 2017

BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints

* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression

09 Nov 2017

BRIEF-Sage Therapeutics announces qtrly loss per share $1.97‍​

* Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update

02 Nov 2017

Wall Street ends at record high, led by banks; Apple weighs

The major Wall Street indexes hit record closing highs on Tuesday, with financial stocks leading the charge, but gains were stunted by a decline in Apple Inc shares after it unveiled its latest line of iPhones. | Video

13 Sep 2017

Financials, industrials boost S&P to record high

The S&P 500 hit a record intraday high on Tuesday, led by gains in financial and industrial stocks after Irma weakened to a tropical depression, but declines in McDonald's and technology stocks weighed on the Dow and Nasdaq.

12 Sep 2017

Sage's seizure drug fails key trial, shares slump

Sage Therapeutics Inc's shares tumbled 23 percent on Tuesday after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.

12 Sep 2017

Earnings vs. Estimates